Kronox Lab Sciences Q4 FY26 Results: PAT Rs 8 Cr

Kronox Lab Sciences Q4 FY26 results were declared on May 21, 2026. The company reported PAT of Rs 8 crore for the quarter ended March 31, 2026, up 33.0% YoY compared to Rs 6 crore in Q4 FY25. Revenue from operations stood at Rs 26 crore, down 0.0% YoY. Results are on a Standalone basis. Kronox Lab Sciences is a Laboratory Chemicals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Kronox Lab Sciences Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	26	26	+0.0%
Gross Profit	Rs 9 crore	7	+28.0%
Net Profit	8	6	+33.0%
Basis	Standalone

Note: Kronox Lab Sciences Q4 FY26 results declared May 21, 2026. Verify from BSE/NSE audited filings before investment decisions.

Kronox Lab Sciences Q4 FY26 Performance Analysis

The Kronox Lab Sciences Q4 FY26 results reflect the company’s operational performance in the January to March 2026 quarter. The company delivered steady performance in line with sector trends. Kronox Lab Sciences operates in the Laboratory Chemicals sector, which benefited from India’s GDP growth above 6.5% in FY26.

Revenue of Rs 26 crore reflects steady business conditions in the Laboratory Chemicals sector.

Screen the best stocks on the Univest Screener.

Key Factors Driving Kronox Lab Sciences Q4 FY26 Results

Revenue and Business Performance

Kronox Lab Sciences Q4 FY26 revenue of Rs 26 crore was down 0.0% YoY. Revenue momentum reflects steady demand in the Laboratory Chemicals business.

Profitability and Margins

the business PAT of Rs 8 crore up 33.0% YoY. The strong PAT growth demonstrates improving operational leverage and cost discipline.

India Macro Backdrop

The January to March 2026 quarter benefited from India’s GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore for FY27, and resilient domestic consumption. RBI’s accommodative stance supported credit and demand conditions. The Laboratory Chemicals sector saw strong tailwinds during this period.

FY27 Outlook

Following the firm results, management commentary on FY27 revenue guidance, margin expansion roadmap, and capital allocation will be key investor watchpoints. The Laboratory Chemicals sector continues to benefit from India’s long-term structural growth.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the company